



**Oramed Pharmaceuticals Inc.**  
**1185 Avenue of the Americas**  
**New York, NY 10036**  
**Phone: 1 844 9 ORAMED**  
**www.oramed.com**

## COMPANY OVERVIEW

- Breakthrough platform technology for oral delivery of drugs and vaccines presently available only via injection
- Pipeline currently focused on diabetes, with potential for a variety of additional treatment indications addressing multi-billion-dollar markets
- Recently completed successful 90-day HbA1c study of ORMD-0801 for oral insulin; this is Oramed's final pivotal Phase 2b study
- Oramed's lead product, oral insulin, has potential to be the first commercial oral insulin
- Robust patent portfolio covering oral delivery, methods of proteins, insulin and GLP-1

## EQUITY OVERVIEW

(as of 11/30/2019)

**Nasdaq/TASE:** ORMP

**Price:** \$4.41

**Market Cap:** \$76.66M

**52 Week Range:** \$2.32-\$5.00

**Avg. Daily Volume (90 day):**  
93.3K

**Shares Outstanding:** 17.4 M

**Cash & Investments:** \$33M (as of  
8/31/19)

## ANALYST COVERAGE

- H.C. Wainwright & Co.
- Ladenburg Thalmann
- Zacks
- Frost & Sullivan

## BETTER WAY TO TREAT DIABETES

**1 in 11 adults**

**1 healthcare**  
**in 8**  
**is spent on diabetes**

**every**  
**6 SECONDS**  
**1 adult dies**  
**from diabetes**  
**4M deaths in 2017**

## INVESTMENT HIGHLIGHTS

### Breakthrough Platform Technology Delivers Injectable Drugs Orally

Oramed's unique Protein Oral Delivery (POD™) technology enables small proteins such as insulin to travel through the gastrointestinal tract and into the bloodstream. This method is more natural and should therefore eliminate the many negative side-effects of injection delivery to the bloodstream. The oral administration of current injection-only therapies for conditions including diabetes, should offer clear benefits including increased compliance and safety, fewer side effects and greater comfort for patients.

### Addressing \$70 Billion Market with Oral Formulations

Roughly \$70 billion worth of drugs and vaccines are currently delivered via injections. This includes the diabetes market where \$24 billion of insulin and \$6 billion of GLP-1 analogs were sold globally in 2017. The vaccine market size was approximately \$33 billion in 2015 and is expected to surpass \$77 billion by 2024.

### Oral Treatment has the potential to Curb Progression of Type 2 Diabetes

ORMD-0801 has the potential to create a new paradigm in the treatment of type 2 diabetes by orally delivering insulin at an earlier stage of treatment. Earlier treatment, in this case by lowering nighttime glucose, can potentially slow disease progression and delay late-stage complications. Oramed concluded a successful Phase IIb study of ORMD-0801 which met its primary endpoints and showed that the drug reduced nighttime glucose levels. Additionally, Oramed successfully completed a 90-day HbA1c study of ORMD-0801, in which the primary cohort achieved a statistically significant lowering of HbA1c. Data from the second cohort, evaluating lower dosing, is expected during the 1Q 2020. Oramed is pursuing a Biologics License Application (BLA) regulatory pathway for ORMD-0801, which would grant a full 12 years of marketing exclusivity if approved.

### Oral GLP-1 Analog to Stimulate Insulin Production in Type 2 Diabetes

Glucagon-like peptide-1 (GLP-1) is a gastrointestinal hormone that stimulates the secretion of insulin from the pancreas. It is beneficial to type 2 diabetic patients by promoting weight loss and decreasing blood sugar. GLP-1 analogs are currently available only via injection. Oramed's ORMD-0901, an oral GLP-1 analog completed two small ex-US clinical trials with encouraging results and a PK study in healthy subjects under an IND in the US.